By the time her cancer was caught, six months after her symptoms began and two days after her 46th birthday, Louise Greenbank's kidneys were failing ...

A world-first blood cancer therapy called belantamab mafodotin (Blenrep) is now available on the NHS in England for multiple ...

The targeted therapy can stop myeloma from progressing by nearly three times as long as existing treatments, studies suggest.

London Tech Week has wrapped for 2025. For a look at this year’s highlights, we’re joined by the Standard’s technology editor, Alex Pell, who not only attended the event but also joined multiple ...

The National Institute for Health and Care Excellence (NICE) has issued a draft guidance recommending GSK’s Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BVd) for ...

England becomes the first country to offer the world’s pioneering 'Trojan horse' blood cancer drug, through NHS, promising ...

UK's health authorities will offer a new targeted treatment for patients suffering from an aggressive blood cancer. This ...

GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

A “TROJAN HORSE” therapy that sneaks toxic drugs inside and kills cancer cells is being rolled out on the NHS in England in a ...

Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...